A.J. Porter - Publications, H-index & Citations

A.J. Porter

elasmogen ltd.

35H指数

169论文数

3.0K被引数

收录论文 52

发表时间

A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload 一种通过理性设计的新型双功能人TNF-α和Janus激酶靶向的soloMER药物偶联物（SDC），其具有中性粒细胞弹性蛋白酶可裂解的连接子，能够实现炎症部位特异性释放有效载荷。

Journal of Medicinal Chemistry

IF6.8

2026-04-07

OAAI

Euan Murray; Stella Priyanka; Julia Martinez-Fraile; Ruslan Grygorash; Mohannad Idress; Luke C. Brownbridge; Stella Glavina; Nicolas Camper; Robert Boyd; Andrew J. Porter; Caroline J. Barelle; Obinna C. Ubah

Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model 时机很重要：在tau重复域靶向的高亲和力抗体早期给药可预防小鼠tau病模型中的聚集。

Alzheimer's Research & Therapy

IF7.6

2026-02-14

OAAI

Lewis K. Penny; Mohammad Arastoo; Richard Lofthouse; Aya Abdallah; Peter I. Imoesi; Karima Schwab; Helen Shiells; Valeria Melis; Gernot Riedel; Charles R. Harrington; Claude M. Wischik; Andrew Porter; Soumya Palliyil

The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors 鲨鱼可变新抗原受体对可溶性TNF-alpha选择性拮抗的结构基础

Nature Communications

IF15.7

2025-11-29

OAAI

Obinna C. Ubah; Eric W. Lake; Kendahl L. Ott; Stella Priyanka; Sasha Celeda; Jayden L. West; Gihan S. Gunaratne; Ke Shi; Nicholas H. Moeller; Andrew J. Porter; Hideki Aihara; David Kosoff; Aaron M. LeBeau; Caroline J. Barelle

High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer's disease

ALZHEIMERS RESEARCH & THERAPY

IF7.6

2024-10-02

OAAI

Arastoo, Mohammad; Penny, Lewis K.; Lofthouse, Richard; Abdallah, Aya; Abrahamsson, Anna; Marini, Pietro; Melis, Valeria; Riedel, Gernot; Harrington, Charles R.; Wischik, Claude M.; Porter, Andrew; Palliyil, Soumya

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease

TRANSLATIONAL NEURODEGENERATION

IF15.2

2024-05-21

OAAI

Penny, Lewis K.; Lofthouse, Richard; Arastoo, Mohammad; Porter, Andy; Palliyil, Soumya; Harrington, Charles R.; Wischik, Claude M.

Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Cranston, Aaron N.; Wappett, Mark; McLean, Estelle G.; Saladino, Chiara; McCann, Aidan; Kung, Wei-Wei; Thom, Jennifer; Trumper, Paul; Porter, Andy; Barelle, Caroline; Harrison, Tim; Cotton, Graham

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis

CELLS

IF5.2

2023-04-18

OAAI

Zabala-Findlay, Alex; Penny, Lewis K.; Lofthouse, Richard A.; Porter, Andrew J.; Palliyil, Soumya; Harrington, Charles R.; Wischik, Claude M.; Arastoo, Mohammad

Functionalization of polymeric nanoparticles with targeting VNAR ligands using vinyl sulfone conjugation

JOURNAL OF MATERIALS CHEMISTRY B

IF5.7

2023-01-01

OAAI

Leach, Adam; Finnegan, Marie; Machado, Mariana S.; Ferguson, Laura; Steven, John; Smyth, Peter; Porter, Andrew; Barelle, Caroline; Themistou, Efrosyni; Scott, Christopher J.

Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2022-04-19

OAAI

Palliyil, Soumya; Mawer, Mark; Alawfi, Sami A.; Fogg, Lily; Tan, Tyng H.; De Cesare, Giuseppe Buda; Walker, Louise A.; MacCallum, Donna M.; Porter, Andrew J.; Munro, Carol A.

Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography

NATURE COMMUNICATIONS

IF15.7

2021-12-16

OAAI

Ubah, Obinna C.; Lake, Eric W.; Gunaratne, Gihan S.; Gallant, Joseph P.; Fernie, Marie; Robertson, Austin J.; Marchant, Jonathan S.; Bold, Tyler D.; Langlois, Ryan A.; Matchett, William E.; Thiede, Joshua M.; Shi, Ke; Yin, Lulu; Moeller, Nicholas H.; Banerjee, Surajit; Ferguson, Laura; Kovaleva, Marina; Porter, Andrew J.; Aihara, Hideki; LeBeau, Aaron M.; Barelle, Caroline J.

Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein

VIRUSES-BASEL

IF3.5

2021-11-02

OAAI

Tan, Tyng Hwey; Patton, Elizabeth; Munro, Carol A.; Corzo-Leon, Dora E.; Porter, Andrew J.; Palliyil, Soumya

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

JOURNAL OF IMMUNOLOGY RESEARCH

IF3.6

2020-02-03

OAAI

Ubah, Obinna C.; Porter, Andrew J.; Barelle, Caroline J.

Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

NANOSCALE

IF5.1

2020-01-01

OAAI

Leach, Adam; Smyth, Peter; Ferguson, Laura; Steven, John; Greene, Michelle K.; Branco, Cristina M.; McCann, Aidan P.; Porter, Andrew; Barelle, Caroline J.; Scott, Christopher J.

An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model

FRONTIERS IN IMMUNOLOGY

IF5.9

2019-03-22

OAAI

Ubah, Obinna C.; Steven, John; Porter, Andrew J.; Barelle, Caroline J.

The composition of contemporary American and Swedish smokeless tobacco products

BMC CHEMISTRY

IF4.6

2019-03-19

OAAI

McAdam, Kevin G.; Kimpton, Harriet; Faizi, Arif; Porter, Andrew; Rodu, Brad

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance

CHEMICAL COMMUNICATIONS

IF4.2

2019-01-01

OAAI

Nogueira, Joao C. F.; Greene, Michelle K.; Richards, Daniel A.; Furby, Alexander O.; Steven, John; Porter, Andrew; Barelle, Caroline; Scott, Christopher J.; Chudasama, Vijay

Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target

ONCOGENE

IF7.3

2018-12-20

OAAI

Abdelwahab, E. M. M.; Pal, S.; Kvell, K.; Sarosi, V; Bai, P.; Rue, R.; Krymskaya, V; McPhail, D.; Porter, A.; Pongracz, J. E.

Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability

BIOCHEMICAL SOCIETY TRANSACTIONS

IF4.3

2018-10-31

PREAI

Ubah, Obinna C.; Buschhaus, Magdalena J.; Ferguson, Laura; Kovaleva, Marina; Steven, John; Porter, Andrew J.; Barelle, Caroline J.

Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development

FRONTIERS IN IMMUNOLOGY

IF5.9

2017-12-22

OAAI

Ubah, Obinna C.; Steven, John; Kovaleva, Marina; Ferguson, Laura; Barelle, Charlotte; Porter, Andrew J. R.; Barelle, Caroline J.

In Vitro Maturation of a humanized shark Vnar Domain to improve its Biophysical Properties to Facilitate clinical Development

FRONTIERS IN IMMUNOLOGY

IF5.9

2017-10-23

OAAI

Steven, John; Mueller, Mischa R.; Carvalho, Miguel F.; Ubah, Obinna C.; Kovaleva, Marina; Donohoe, Gerard; Baddeley, Thomas; Cornock, Dawn; Saunders, Kenneth; Porter, Andrew J.; Barelle, Caroline Jane

研究方向